AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically ...
With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...
Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...
Over 2 decades ago, the aldosterone antagonist eplerenone proved beneficial after MI complicated by left ventricular ...
Patients with GPA completely weaned off glucocorticoids were four times as likely to flare compared with those kept on a low ...
Michigan’s pension bought Palantir, Intel, and CVS Health stock, while slashing an investment in Bristol Myers in the third ...
Health stocks slumped on Friday as Wall Street weighed the impact that prominent vaccine skeptic Robert F. Kennedy Jr. could ...
Why one trial participant's healthy birth after her CAR-T treatment for lupus is catching resesarchers' attention: ...
Bristol Myers Squibb (BMY) has received a recommendation for approval from an expert panel of the European Medicines Agency ...
Bristol Myers Squibb on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanded approval of its Augtyro cancer drug in a pair of indications.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback